Will Supernus (SUPN) Beat Estimates Again in Its Next Earnings Report?
Supernus (SUPN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Zacks · 07/30 16:10
Earnings Preview: Supernus Pharmaceuticals (SUPN) Q2 Earnings Expected to Decline
Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 07/28 16:33
These 3 Biotech Stocks Are Outperforming Their Peers Here's Why
Investor's Business Daily · 07/07 15:00
5 Things To Know If You Want To Beat The Market
Seeking Alpha - Article · 07/06 11:51
Supernus Sues Apotex for Infringement of Oxtellar XR® Patents
Supernus Pharmaceuticals, Inc. (SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced that earlier today it sued generic drug maker Apotex Inc. and Apotex Corp.
GlobeNewswire · 06/26 22:29
Supernus Pharmaceuticals Inc (SUPN): Hedge Funds Are Snapping Up
Insider Monkey · 06/18 15:19
Supernus' Makeover: A Work In Progress
Seeking Alpha - Article · 06/16 12:23
Piper Sandler Upgrades Supernus Pharmaceuticals to Overweight, Raises Price Target to $31
Piper Sandler analyst David Amsellem upgrades Supernus Pharmaceuticals (NASDAQ:SUPN) from Neutral to Overweight and raises the price target from $25 to $31.